PRENETICS HOLDING COMPANY LIMITED
NASDAQ: PRENW (Prenetics Holding Company Limited)
Last update: yesterday, 9:18AM0.029
0.01 (59.12%)
| Previous Close | 0.018 |
| Open | 0.022 |
| Volume | 24,400 |
| 52 Weeks Range |
| Profit Margin | -115.91% |
| Operating Margin (TTM) | -61.41% |
| Diluted EPS (TTM) | -11.04 |
| Quarterly Revenue Growth (YOY) | 169.90% |
| Total Debt/Equity (MRQ) | 3.20% |
| Current Ratio (MRQ) | 2.07 |
| Operating Cash Flow (TTM) | -28.87 M |
| Levered Free Cash Flow (TTM) | -9.90 M |
| Return on Assets (TTM) | -14.52% |
| Return on Equity (TTM) | -28.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Prenetics Holding Company Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.67 |
|
Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aspex Management (Hk) Ltd | 30 Sep 2025 | 1,166,666 |
| Vestcor Inc | 30 Sep 2025 | 66,666 |
| Oasis Management Co Ltd. | 30 Sep 2025 | 33,333 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |